# Pizarra — PT-pseudo_259484ae733f (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_259484ae733f
Task: 1

Encounter: Urology - outpatient on 04 Jan 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 5.3 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.092 ng/mL²
  - PSA velocity: 1.37 ng/mL/yr
  - Prior PSA: 4.3 ng/mL
  - Prostate volume: 57.56 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.79137033 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 5.3 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 58 mL. csPCa 0.79.

Vitals: weight 115 kg, height 190 cm, BMI 31.9, BP 132/83 mmHg, HR 81 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2021).

Chief complaint: Current visit addresses a PSA escalation to 5.3 ng/mL against the backdrop of a prior biopsy yielding ISUP grade group 2.

History: First assessed for an elevated PSA reading in late 2023, this 65-year-old man has undergone regular serial testing since. A 30 pack-year smoking history is noted, with cessation achieved in 2021. He operates as an independent delivery driver and requested appointment times that accommodate his schedule. Married status applies, yet he resides by himself; his adult daughter acts as the main emergency contact. Lower urinary tract complaints are moderate, quantified at an IPSS of 13, and currently require no pharmacological intervention. Daily walks lasting twenty minutes form part of his routine, alongside a weekly alcohol consumption capped at two units. A 2018 knee arthroscopy stands as his only significant past surgical event, while recent memory and hearing evaluations returned normal results.

Physical examination: DRE — texture: smooth and firm; dimensions: symmetrically enlarged; palpation: negative for nodules or asymmetry. Systemic assessment shows stable vitals with no evidence of acute or chronic systemic disease.

Patient info: delivery driver; Married; Lives alone; adult daughter is primary contact.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 2 units / week; exercise Walking 20 min/day; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Memory clinic — baseline screening; Audiology — hearing test; Pulmonary function test — known COPD follow-up.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.51 +/- 0.19   (95% CI 0.15-0.87)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 7.8 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=5.3, age=65.0, psad=0.092, dre_ord=0.0, vol=57.56, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the PSA velocity (1.37 ng/mL/yr) against the prior PSA (4.3 ng/mL) and the current PSA (5.3 ng/mL), which suggests a rapid escalation. It also could not incorporate the specific details from the mpMRI report (beyond the PI-RADS 4) or the full laboratory panel, which might contain markers influencing the csPCa probability.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a 'discuss' tier decision (0.51 +/- 0.19). A failure mode is the high csPCa predicted probability (0.79137033) conflicting with the prior positive biopsy status, making the question "does he have cancer" inappropriate. Another failure mode is the DRE being 'Normal' despite the elevated PSA and PI-RADS 4, which might suggest the prior biopsy result is highly relevant, or the DRE finding is misleading.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant intraprostatic extension or suspicious lesions beyond the PI-RADS 4, it would increase the need for biopsy.
  <document> PSA history (trend) -> If the trend shows a steeper rise or a more concerning trajectory than implied by the single velocity value, it would increase the need for biopsy.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the prior biopsy result (ISUP grade 2) and the clinical rationale for the current re-evaluation.
  <document> laboratory results (full panel) -> This could reveal other markers that modify the risk assessment, especially in light of the high csPCa probability.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  Amsterdam UMC (VUmc) Radiology | 04 January 2025
  Clinical indication: Assessment of a PSA reading of 5.3 ng/mL alongside a historically positive biopsy.
  FINDINGS: The gland spans a volume of 57.56 mL. T2 sequences highlight an 18 mm focal hypointense focus at the posterior left peripheral zone. Diffusion-weighted imaging shows pronounced restriction, mirrored by low ADC signal. Dynamic contrast studies capture early, focal enhancement against the background parenchyma. Extracapsular extension and seminal vesicle invasion are absent. Pelvic lymph nodes and the bladder appear normal.
  IMPRESSION: PI-RADS 4 lesion in the left peripheral zone. PSAD 0.092 ng/mL/mL. csPCa predicted probability 0.79137033.

  **psa_trend**
  {"date": "Oct 2023", "val": 3.3}, {"date": "Feb 2024", "val": 3.7}, {"date": "May 2024", "val": 4.2}, {"date": "Sep 2024", "val": 4.7}, {"date": "Jan 2025", "val": 5.3}

  **previous_notes**
  {"date": "10 Jan 2024", "author": "Dr. T. Hendriks (GP)", "text": "On 10 January 2024, Dr. T. Hendriks documented a PSA trajectory climbing from 1.7 ng/mL in October 2023 to 2.7 ng/mL by February 2024. In light of a previously positive biopsy and an IPSS score of 13 reflecting moderate lower urinary tract symptoms, a urology clinic referral was arranged for comprehensive assessment."}

  **lab_results**
  {"name": "PSA", "val": "5.3 ng/mL", "date": "21 Nov 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.29 ng/mL", "date": "21 Nov 2024", "flag": ""}, {"name": "%Free PSA", "val": "24%", "date": "21 Nov 2024", "flag": ""}, {"name": "Haemoglobin", "val": "15.6 g/dL", "date": "21 Nov 2024", "flag": ""}, {"name": "WBC", "val": "8.0 x10^9/L", "date": "21 Nov 2024", "flag": ""}, {"name": "Platelets", "val": "230 x10^9/L", "date": "21 Nov 2024", "flag": ""}, {"name": "Creatinine", "val": "103 umol/L", "date": "21 Nov 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "21 Nov 2024", "flag": ""}, {"name": "Testosterone", "val": "10.2 nmol/L", "date": "21 Nov 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "104 U/L", "date": "21 Nov 2024", "flag": ""}, {"name": "LDH", "val": "181 U/L", "date": "21 Nov 2024", "flag": ""}}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 4 lesion in the left peripheral zone
  PSA velocity of 1.37 ng/mL/yr (from prior data)
  csPCa predicted probability of 0.79137033

  AGAINST sampling this patient now:
  DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high PI-RADS score (4) and the rapidly rising PSA trend, which aligns with the statistical prior's suggestion of BIOPSY. This leans toward confirming the high csPCa probability despite the prior positive result.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports sampling due to the PI-RADS 4 lesion and the rapidly rising PSA trend. The decisive factors are the PI-RADS 4 score and the PSA velocity of 1.37 ng/mL/yr, which align with the statistical prior's suggestion. Although the prior biopsy was positive, the new high-risk imaging features and PSA escalation warrant re-biopsy to confirm the high csPCa probability of 0.79137033.

Variables that carried weight: bx=decisive, dre=noted, psa=decisive, psad=important, cspca=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
